“We are delighted to extend our analytical capacity with the highest-performing instrument on the market in mass spectrometry, the Thermo Orbitrap Astral. The major advantage is that it can perform extensive analyses quickly while maintaining high analytical sensitivity,” says Carina Sihlbom Wallem, Head of Proteomics Core Facility (PCF).
A Rapidly Developing Field
Mass spectrometry is an analytical detection method in proteomics where instruments are evolving at a very fast pace, with sensitivity constantly improving. The new instrument, with its high capacity, will better support large-scale clinical studies and is expected to have an essential impact on the development of precision medicine.
Aiming for Early Detection of Disease
“Protein analysis, or proteomics, is as important as genomics for medical research,” continues Carina Sihlbom Wallem. “Proteomics is used to identify disease biomarkers by mapping proteins involved in disease development. Biomarkers expressed early in the disease are of particular interest for enabling earlier diagnosis and better treatment options. A challenge in identifying these protein markers is that they are often present in much lower concentrations compared to later stages. Therefore, a method’s analytical sensitivity is often crucial. Our new instrument provides better capabilities.”
The instrument, which cost 13.5 million SEK, was delivered at the end of last year, and installation and training are currently underway. The PCF unit not only provides the instrumentation but also possesses expertise in the field. Carina herself has extensive experience and leads a team of twelve specialists. Currently, the PCF supports around eighty research groups per year, representing a large range of disciplines, with at least half of them coming from the University of Gothenburg or Sahlgrenska University Hospital.
“Furthermore, better sensitive proteomic analysis not only allows us to find biomarkers earlier but also to understand disease mechanisms in more detail. This can contribute to the development of new therapies and more personalized medicine, where treatment is tailored to the patient’s specific protein profile. If a treatment has worked well for a particular patient, it is more likely that the same treatment will also work for another patient who is a ‘molecular twin’ with the same protein profile.”
More about Proteomics Core Facility
